EMA backs datopotamab deruxtecan, but lung cancer access remains unclear

EMA backs datopotamab deruxtecan, but lung cancer access remains unclear

EMA recommended datopotamab deruxtecan in Europe, but the supported EU approval in the evidence base is for HR-positive, HER2-negative breast cancer rather than lung cancer. In the U.S., DATROWAY has accelerated approval for EGFR-mutated NSCLC, making this a key catalyst-tracking update for BD teams and investors. The EMA approval for datopotamab deruxtecan diverges sharply from the FDA approval pathway.

IntelligenceRegulatory Impact▾

EMA and FDA decisions frame this story. Regulatory relevance is high for lung cancer, with datopotamab deruxtecan and DATROWAY most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.

Key Takeaways

• The FDA granted accelerated approval to datopotamab deruxtecan-dlnk on June 23, 2025, for adult patients with locally advanced or metastatic EGFR-mutated NSCLC who have received prior EGFR-directed therapy and platinum-based chemotherapy.
• AstraZeneca and Daiichi Sankyo voluntarily withdrew the EU marketing authorization application for datopotamab deruxtecan in NSCLC, creating a divergence between U.S. and European regulatory pathways.
• Datopotamab deruxtecan was approved in the European Union for unresectable or metastatic hormone receptor positive, HER2 negative breast cancer in patients who have received endocrine therapy.
• TROPION-Lung01 demonstrated that datopotamab deruxtecan significantly improved progression-free survival versus docetaxel in advanced or metastatic NSCLC, particularly in the nonsquamous population.

IntelligenceCompetitive Intelligence▾

AstraZeneca and Daiichi Sankyo are directly implicated. Competitive pressure reads medium — compare pipeline positioning and partnership scouting against signals in this story.

Regulatory development: U.S. approval, EU withdrawal

DATROWAY (datopotamab deruxtecan), manufactured by Daiichi Sankyo Inc., is a Trop-2-directed antibody and topoisomerase inhibitor conjugate that received accelerated FDA approval for a narrowly defined patient population. The approval covers adult patients with locally advanced or metastatic EGFR-mutated NSCLC who have previously received EGFR-directed therapy and platinum-based chemotherapy. The indication was granted under accelerated approval based on objective response rate and duration of response, with continued approval contingent on verification of clinical benefit in a confirmatory trial.

The European regulatory path diverged sharply. AstraZeneca and Daiichi Sankyo voluntarily withdrew the marketing authorization application in the EU for datopotamab deruxtecan as a treatment for adult patients with locally advanced or metastatic NSCLC. Instead, DATROWAY received EU approval for unresectable or metastatic hormone receptor positive, HER2 negative breast cancer in patients who have received endocrine therapy.

For BD teams and investors, this divergence highlights a critical difference in regulatory outcomes between jurisdictions. The U.S. approval is biomarker-specific and narrow; the EU approval is in a different indication entirely. The voluntary withdrawal of the NSCLC application in Europe means that neither regulatory jurisdiction currently supports the same NSCLC label.

IntelligenceMarket Signals▾

Commercial pull is high and investment relevance high for lung cancer. Expect implications for pricing, access, and launch sequencing.

Clinical evidence from TROPION-Lung01

In the TROPION-Lung01 study, datopotamab deruxtecan significantly improved progression-free survival versus docetaxel in patients with advanced or metastatic NSCLC, with the benefit driven by patients with nonsquamous histology. This trial represents the clinical foundation for lung cancer development and supports ongoing evaluation in broader NSCLC populations.

The clinical signal in TROPION-Lung01 provides the evidence base for the FDA's accelerated approval decision. The trial data satisfied the FDA's threshold for accelerated approval based on response endpoints. The EU's decision to withdraw the NSCLC application represents a different regulatory path, though the specific reasons for withdrawal are not disclosed in the public record.

IntelligenceStrategic Takeaways▾

The FDA granted accelerated approval to datopotamab deruxtecan-dlnk on June 23, 2025 , for adult patients with locally advanced or metastatic EGFR-mutated NSCLC who have received prior EGFR-directed therapy and platinum-based chemotherapy. AstraZeneca and Daiichi Sankyo voluntarily withdrew the EU marketing authorization application for datopotamab deruxtecan in NSCLC , creating a divergence between U.S. and European

What the FDA label actually covers

The FDA indication for DATROWAY is limited to adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer who have received prior EGFR-directed therapy and platinum-based chemotherapy. This is a heavily pretreated population—patients who have already failed both targeted therapy and chemotherapy. The label does not extend to treatment-naïve patients, first-line settings, or NSCLC without EGFR mutations.

The accelerated approval pathway means the indication rests on response data pending confirmation of clinical benefit. The agency has included a requirement for continued approval contingent on verification of clinical benefit in a confirmatory trial.

IntelligenceEvidence Quality▾

Grounded in 4 regulatory sources and 1 peer-reviewed source.

Ongoing clinical development and catalyst timeline

Multiple trials are currently enrolling or active, creating a pipeline of potential data readouts. NCT07291037 is a Phase III study of datopotamab deruxtecan versus docetaxel in previously treated TROP2-positive advanced or metastatic non-squamous NSCLC without actionable genomic alterations, currently recruiting. This trial expands the population beyond EGFR-mutated patients, testing whether the drug has utility in a broader NSCLC segment.

NCT05061550 is a Phase II study of neoadjuvant and adjuvant treatment in resectable non-small cell lung cancer, also recruiting. NCT05687266 is a Phase III, open-label, first-line study of datopotamab deruxtecan in combination with durvalumab and carboplatin for advanced NSCLC without actionable genomic alterations, currently active but not recruiting.

Beyond lung cancer, NCT06954480 is a Phase II study investigating datopotamab deruxtecan plus durvalumab versus datopotamab deruxtecan in patients with PDL1-negative metastatic triple-negative breast cancer, recruiting. These trials represent ongoing clinical development across multiple indications, though results are not yet available.

Market access and regulatory considerations

The evidence base does not contain information about payer coverage, reimbursement status, or market access decisions in either the U.S. or Europe. The narrow FDA indication—limited to EGFR-mutated, heavily pretreated NSCLC—defines the current approved population, but specific coverage policies or pricing are not available in the regulatory or clinical record.

The EU withdrawal of the NSCLC application creates a regulatory divergence. The approved EU indication is for unresectable or metastatic hormone receptor positive, HER2 negative breast cancer, not lung cancer.

Investor and BD implications

For investors and BD teams, the story centers on regulatory divergence and label specificity. The FDA approval is real and represents a new treatment option for a specific, highly pretreated patient population. The accelerated approval status means the indication is contingent on confirmation of clinical benefit in a follow-up study.

The EU withdrawal of the NSCLC application represents a different regulatory outcome from the U.S. pathway. This divergence is material for multinational companies and investors evaluating the asset's global commercial potential.

The ongoing trial portfolio—particularly NCT07291037 testing a broader TROP2-positive NSCLC population and NCT05687266 testing a first-line combination—represents future data points. Results from these studies will inform whether label expansions or new regulatory filings are pursued.

What to watch next

• Results from the confirmatory trial required as a condition of continued FDA approval for EGFR-mutated NSCLC.
• Data from NCT07291037, the Phase III study in TROP2-positive non-squamous NSCLC without actionable genomic alterations.
• Outcomes from NCT05687266, testing first-line datopotamab deruxtecan in combination with durvalumab and carboplatin for advanced NSCLC without actionable genomic alterations.
• Any future regulatory filings or applications in the EU for NSCLC or other indications.
• Enrollment and safety updates from NCT07357597, a Phase IV study of prophylaxis for datopotamab deruxtecan-related stomatitis.

Frequently Asked Questions

Related profiles

• AstraZeneca
• datopotamab deruxtecan
• datopotamab deruxtecan-dlnk
• dato-dxd
• Daiichi Sankyo US

Related coverage

• EMA backs datopotamab deruxtecan for advanced lung cancer
• AstraZeneca and Daiichi Sankyo datopotamab deruxtecan hits lung cancer endpoint
• FDA approves Keytruda for adjuvant NSCLC treatment, expanding Merck’s lung cancer label